TrialTrials2016

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.

Philip C Schouten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.